Bristol-Myers Squibb is committed to discovering, developing and delivering innovative medicines for the treatment of cancer. Our pipeline in oncology is robust, with approximately 25 experimental anticancer compounds in development. It is also diverse, reflecting a range of modalities and research programs. One such area is immuno-oncology.
Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. We are at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses.
The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
Cancer represents a multitude of diseases. We concentrate our efforts on cancer types where the unmet medical needs, as measured by gaps in current therapies and the magnitude of the burden on public health, are especially high. These include lung cancer, prostate cancer, melanoma, gastrointestinal cancer and hematologic cancers.
Cancer is also a leading cause of death worldwide, and a disease we view with a global perspective. Our program in gastric and esophageal cancers, for example, responds to needs in the Asia Pacific region where the prevalence of these conditions is higher.
Great advances have been made in the prevention, early detection and treatment of many forms of cancer. Great challenges and unmet needs remain. Bristol-Myers Squibb has been on the leading edge of cancer treatment since the 1970s and continues to be committed to developing new and improved treatment options that give patients hope.